J&J unblinds prostate cancer drug study; Aegerion names new CEO

@FierceBiotech: Four drugs look to pass FDA muster this month. Report | Follow @FierceBiotech

@JohnCFierce: Seattle Genetics CEO did a good job softening the blow on its trial failure; shares down about 18% anyway. | Follow @FierceBiotech

> J&J decided to unblind its Phase III study of the prostate cancer drug abiraterone acetate after the monitoring committee determined that the patients in the placebo group should be offered the therapy. The trial enrolled 1,195 patients. Report

> Aegerion Pharmaceuticals named Marc Beer, the founding CEO of ViaCell, as both CEO and a member of the board of directors. Aegerion release

> Ariad Pharmaceuticals and Cyclacel Pharmaceuticals each announced plans to move blood cancer therapies into late-stage trials. Story

> Athersys is pocketing a $3 million upfront after it agreed to provide RTI Biologics access to its Multipotent Adult Progenitor Cell technologies. RTI release

And Finally... Scientists say they've found a plant that can clone itself in order to survive environmental chaos, a helpful lesson for surviving climate change. Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.